Domain Therapeutics launches Specific Purpose Vehicle Kaldi Pharma to harness the potential of its adenosine programs
4 March 2015 | By Domain Therapeutics
Kaldi Pharma granted its first license to CleveXel Pharma, who will develop a preclinical candidate for Parkinson’s disease...